List of Excipients in Branded Drug INSULIN LISPRO

Insulin Lispro Excipient Strategy and Commercial Opportunities

Last updated: August 22, 2026

Insulin lispro is a mature rapid-acting insulin with three main commercial formulation strategies: conventional zinc-phosphate stabilization, biosimilar or follow-on replication, and accelerated-absorption formulations using permeation-enhancing excipients. The largest opportunity is not basic insulin lispro supply. It is differentiated delivery, concentrated dosing, pump compatibility, preservative optimization, and lower-cost manufacturing.

Humalog and Admelog use conventional excipient systems built around m-cresol, glycerol, phosphate buffer, and zinc. Lyumjev uses a different system that includes tromethamine, magnesium chloride, and excipients intended to accelerate subcutaneous absorption. These differences create commercial opportunities in rapid-onset products, preservative-free presentations, high-concentration insulin, connected delivery systems, and emerging markets.

What excipients are used in insulin lispro products?

The principal U.S. insulin lispro products are Humalog, Admelog, and Lyumjev. Their excipient systems differ materially.

Product	Active ingredient	Strengths	Key excipients	Commercial positioning
Humalog	Insulin lispro	U-100, U-200	m-Cresol, glycerol, dibasic sodium phosphate, zinc oxide, water	Originator rapid-acting insulin
Admelog	Insulin lispro	U-100	m-Cresol, glycerol, phosphate buffer, zinc oxide, water	Follow-on insulin lispro and lower-cost competitor
Lyumjev	Insulin lispro-aabc	U-100, U-200	m-Cresol, glycerol, tromethamine, magnesium chloride, zinc oxide, water	Ultra-rapid formulation
Generic or regional lispro products	Insulin lispro	Usually U-100	Generally similar preservative, buffer, polyol, and zinc systems	Price competition and regional access

Humalog U-100 contains m-cresol at approximately 3.15 mg/mL, glycerol at approximately 16 mg/mL, dibasic sodium phosphate, zinc oxide, and water. The formulation is adjusted to an acidic-to-neutral range suitable for insulin stability and injection.

Admelog uses a substantially similar excipient architecture. This similarity supports regulatory comparability and reduces technical barriers for follow-on manufacturers.

Lyumjev uses m-cresol and glycerol but replaces the conventional phosphate-buffer system with tromethamine and magnesium chloride. The product also uses excipients associated with faster absorption after subcutaneous administration. The formulation is designed to reduce the delay between injection and systemic insulin exposure compared with conventional insulin lispro products. [1-3]

How do Humalog, Admelog, and Lyumjev formulations compare?

Humalog and Admelog

Humalog and Admelog are conventional rapid-acting insulin lispro products. Their key formulation functions are:

• m-Cresol preserves the multidose vial, cartridge, and pen formulation against microbial contamination.
• Glycerol adjusts tonicity and contributes to formulation stability.
• Phosphate provides buffering capacity.
• Zinc supports insulin association and molecular stability.
• Water is the injection vehicle.
• Hydrochloric acid or sodium hydroxide may be used for pH adjustment.

The commercial advantage of this excipient platform is manufacturing familiarity. Suppliers can source the principal excipients at pharmaceutical grade, and contract manufacturers have extensive experience with comparable insulin systems.

The limitation is differentiation. A product using the same excipients and the same insulin sequence will compete primarily on price, device design, supply reliability, regulatory status, and distribution.

Lyumjev

Lyumjev modifies the excipient system to promote faster absorption. Its formulation includes tromethamine and magnesium chloride in addition to m-cresol, glycerol, and zinc. The product also uses absorption-enhancing components that support more rapid pharmacokinetics after subcutaneous dosing.

The formulation strategy creates a stronger product proposition than a conventional lispro follow-on, but it raises technical and regulatory complexity. Developers must demonstrate:

• Chemical and physical stability of insulin lispro in the presence of absorption enhancers.
• Compatibility with vials, cartridges, prefilled pens, and infusion devices.
• Local tolerability and injection-site safety.
• Pump reservoir stability and occlusion performance.
• Consistent absorption across injection sites and patient populations.
• Manufacturing control of low-concentration excipients with pharmacological effects.

A faster-acting lispro product can command greater commercial value than a conventional biosimilar if clinical evidence shows meaningful improvements in postprandial glucose control, time in range, or dosing flexibility.

What excipient functions matter most in insulin lispro development?

Excipient selection is constrained by insulin’s sensitivity to aggregation, adsorption, oxidation, deamidation, agitation, temperature, and interfacial stress.

Preservative strategy

Multidose insulin products require antimicrobial preservation. M-Cresol is widely used because it has an established history in insulin formulations and supports multidose container closure systems.

The commercial opportunity lies in reducing preservative burden without compromising multidose safety. Potential approaches include:

• Lower-preservative formulations for patients with injection-site sensitivity.
• Preservative-free single-use cartridges or disposable devices.
• Alternative antimicrobial systems with improved tolerability.
• Device systems that reduce repeated microbial exposure.
• Closed-loop delivery systems with controlled reservoir replacement.

Any change to preservative content creates a comparability burden. The developer must establish antimicrobial effectiveness, container compatibility, extractables and leachables performance, and shelf life.

Zinc management

Zinc promotes insulin hexamer formation and helps control the conversion of insulin between associated and dissociated states. Zinc concentration affects stability, subcutaneous depot behavior, and absorption.

A lower-zinc formulation may support faster monomer availability, while higher or better-controlled zinc levels may improve physical stability. The opportunity is to balance rapid onset with a commercially acceptable shelf life.

Zinc chemistry also affects pump compatibility. Adsorption to reservoir surfaces, tubing, and infusion-set materials can change effective dose delivery. Products designed for pump use require specific compatibility evidence rather than reliance on subcutaneous injection data.

Buffer selection

Phosphate, tromethamine, citrate, and related buffers can affect insulin association, pH stability, metal interactions, and local tolerability.

The buffer system should be selected around the intended product profile:

Product objective	Excipient strategy
Conventional low-cost lispro	Phosphate, glycerol, zinc, and m-cresol
Faster subcutaneous absorption	Buffer and ionic conditions that promote rapid insulin availability
Pump use	Low adsorption, low precipitation, and reservoir compatibility
High concentration	Tight control of viscosity, aggregation, and injection force
Long shelf life	Buffer and metal-ion control with robust stress stability
Single-use presentation	Reduced or absent preservative load

Surfactants and aggregation control

Insulin can adsorb to glass, plastic, silicone oil, tubing, and air-liquid interfaces. Surfactants may reduce interfacial aggregation, but they can also create regulatory and manufacturing issues.

Potential excipients include low levels of polysorbates or other protein-compatible surfactants. The main development risks are peroxide-mediated oxidation, surfactant degradation, particle formation, and container interaction. A surfactant strategy is more attractive for pump reservoirs and wearable delivery systems than for a simple vial copy.

What formulation patents protect insulin lispro products?

Insulin lispro intellectual property has historically covered the insulin sequence, recombinant production, formulations, delivery systems, cartridges, pens, pumps, and rapid-absorption compositions.

The original Humalog composition and use patents are mature. Basic composition-of-matter protection for insulin lispro no longer provides a meaningful barrier to conventional follow-on products in the United States. Competitive protection has shifted toward:

• Ultra-rapid absorption formulations.
• Specific excipient combinations.
• Concentrated insulin products.
• Stable formulations for infusion pumps.
• Pen and cartridge systems.
• Dosing algorithms and connected delivery.
• Manufacturing processes and impurity controls.
• New methods of treating postprandial hyperglycemia.

Patent risk remains product-specific. A developer can avoid expired core claims while still encountering later patents covering a particular excipient combination, concentration, device, or method of use. A freedom-to-operate review should examine U.S., European, Canadian, Japanese, Chinese, and other national patent families separately because claim scope and litigation outcomes vary by jurisdiction.

Insulin products approved under the biologics pathway are generally assessed through the Purple Book rather than the traditional small-molecule Orange Book framework. FDA’s transition of insulin products from the drug pathway to the biologics pathway took effect in March 2020. [4]

What is the FDA regulatory status of insulin lispro products?

Humalog was originally approved as a drug product and is now regulated as a biologic insulin product. Admelog was approved by FDA as a follow-on insulin lispro under the 351(k) biosimilar pathway. Lyumjev was approved as a new insulin lispro-aabc product with an ultra-rapid pharmacokinetic profile. [1-4]

Regulatory issue	Humalog	Admelog	Lyumjev
U.S. approval	Yes	Yes	Yes
Regulatory category	Insulin biologic	Biosimilar/follow-on insulin	New insulin lispro-aabc biologic
U-100	Yes	Yes	Yes
U-200	Yes	No broadly marketed U.S. equivalent	Yes
Pump use	Product-specific labeling	Product-specific labeling	Product-specific labeling
Primary differentiation	Brand, installed base, devices	Price and access	Faster onset
Orange Book relevance	Limited after biologics transition	Limited after biologics transition	Limited after biologics transition

Regulatory approval does not automatically establish interchangeability. FDA biosimilar status and interchangeable biosimilar status are distinct designations. Product substitution depends on the approved label, state pharmacy law, payer rules, and the manufacturer’s commercial strategy.

When does insulin lispro lose exclusivity?

Conventional insulin lispro has already lost the principal exclusivity associated with the original Humalog product. The commercial market is therefore open to follow-on insulin lispro products, subject to regulatory approval, manufacturing capability, supply controls, and device compatibility.

The relevant exclusivity categories are now:

• Product-specific biologic exclusivity.
• Pediatric exclusivity, where applicable.
• New indication or new formulation exclusivity.
• Patent protection for later-developed formulations.
• Device and delivery-system patent protection.
• Regulatory exclusivity associated with a distinct biologic product.

For a new excipient-enhanced lispro product, the strongest commercial protection is likely to come from a combination of formulation patents, clinical differentiation, device integration, and manufacturing know-how. A formulation patent alone may not prevent price competition if a rival can use a different absorption-enhancing system.

Which companies are challenging the insulin lispro market?

The market includes originator companies, biosimilar manufacturers, insulin specialists, contract manufacturers, and device companies.

Eli Lilly

Eli Lilly markets Humalog and Lyumjev. Its strategic advantage is the combination of insulin manufacturing, global distribution, pen technology, pump partnerships, and clinical familiarity. Lyumjev provides a differentiated platform that is less exposed to pure biosimilar pricing than conventional Humalog.

Sanofi

Sanofi markets Admelog. Its opportunity is concentrated in formulary access, payer contracting, manufacturing scale, and lower-cost competition against Humalog. Admelog demonstrates that insulin lispro competition can be established without reproducing every commercial attribute of the originator product.

Biocon, Wockhardt, and regional manufacturers

Regional insulin manufacturers can compete through lower production costs, local regulatory approvals, government tenders, and domestic fill-finish capacity. The strongest opportunities are in markets where insulin access programs favor price, local production, or public procurement.

The technical hurdle is not only production of recombinant insulin. It is consistent control of impurities, aggregation, potency, sterility, container closure, cold-chain performance, and device delivery.

What commercial opportunities exist for insulin lispro excipients?

Lower-cost conventional lispro

The most direct opportunity is a U-100 insulin lispro product using a conventional excipient platform. The development program can minimize risk by using familiar excipients and established container systems.

Commercial success depends on:

• Cost of goods.
• Reliable insulin substance supply.
• Pen and cartridge manufacturing.
• Payer coverage.
• Wholesale acquisition price.
• Government tender access.
• Cold-chain distribution.
• Ability to support multiple presentation sizes.

This is a scale business with limited formulation differentiation.

Ultra-rapid lispro

An absorption-enhanced lispro product can target patients who need closer alignment between insulin dosing and meals. The product may also compete in automated insulin delivery, where faster pharmacokinetics can improve algorithm performance.

The opportunity is strongest when the formulation demonstrates a measurable clinical benefit rather than only a pharmacokinetic difference. Evidence in postprandial glucose control, time in range, and dosing after meals supports stronger reimbursement arguments.

High-concentration insulin lispro

U-200 lispro reduces injection volume for patients with high daily insulin requirements. Excipient development must address:

• Increased solution viscosity.
• Injection force through pen needles.
• Aggregation at higher protein concentration.
• Device dose accuracy.
• Cartridge and stopper compatibility.
• Pump restrictions and labeling.
• Human-factors performance.

High-concentration products can protect revenue by improving convenience and reducing injection burden. They also create opportunities for device manufacturers and specialty distributors.

Pump-compatible lispro

Insulin pump users require formulation and device data that differ from pen or vial users. The product must maintain potency during extended residence in the reservoir and tubing.

Commercial opportunities include:

• Dedicated lispro for patch pumps.
• Low-adsorption formulations.
• Longer reservoir dwell time.
• Reduced occlusion rates.
• Compatibility with automated insulin delivery systems.
• Stability under heat and mechanical agitation.

Pump formulations can produce stronger customer retention because switching requires device, clinical, and training coordination.

Preservative-reduced and single-use formats

A single-use insulin lispro cartridge or microdose presentation could reduce preservative exposure and simplify use in wearable systems. The market is smaller than the standard multidose pen market but may support premium pricing where tolerability, convenience, or device integration is important.

Excipients for emerging markets

A lower-cost excipient platform may support products for markets with less sophisticated cold-chain infrastructure. The formulation must tolerate temperature excursions without unacceptable potency loss or aggregation.

Potential commercial models include:

• Regional fill-finish licensing.
• Local manufacturing of cartridges and vials.
• Government procurement agreements.
• Technology transfer with insulin substance supplied centrally.
• Dual sourcing of m-cresol, glycerol, zinc, and buffer components.

How strong is the patent estate for insulin lispro excipient innovation?

The patent estate is strongest for differentiated products rather than conventional lispro copies.

Innovation area	Patent strength	Regulatory burden	Commercial value
Conventional m-cresol/glycerol/phosphate formulation	Low to moderate	Moderate	Low to moderate
New rapid-absorption excipient combination	Moderate to high	High	High
U-200 or higher concentration	Moderate	High	High
Pump-stable formulation	Moderate	High	Moderate to high
Preservative-free single-use product	Moderate	Moderate to high	Niche to moderate
Novel pen or wearable reservoir	Moderate to high	Moderate to high	High
Manufacturing impurity-control process	Moderate	High	Moderate
Generic excipient substitution	Low	Moderate	Low

Patent durability improves when the formulation is linked to a measurable performance limitation, such as faster absorption, extended pump stability, reduced aggregation, or improved injection-force characteristics. Broad claims to familiar excipients face greater validity and design-around risk.

What generic launch risks exist for insulin lispro?

A conventional generic or biosimilar lispro launch can occur without copying the originator’s full commercial platform. The main risks are:

1. Regulatory comparability failure.
2. Inconsistent insulin potency or impurity profiles.
3. Device compatibility problems.
4. Payer exclusion despite regulatory approval.
5. Supply interruptions caused by limited recombinant capacity.
6. Patent claims covering a specific formulation or delivery device.
7. Patient and prescriber resistance to switching.
8. Manufacturing failures involving aggregation, particles, or sterility.

A lower-price product has the best launch prospects when it combines an approved pen presentation, established pharmacy distribution, payer contracts, and sufficient inventory. A vial-only launch may reduce manufacturing cost but limit uptake among patients using disposable or reusable pens.

What licensing and partnership opportunities exist?

The most commercially relevant licensing targets are not only insulin sequences. They include:

• Rapid-absorption excipient systems.
• Stable high-concentration formulations.
• Pump-compatible insulin compositions.
• Prefilled pen platforms.
• Wearable insulin delivery reservoirs.
• Recombinant insulin manufacturing technology.
• Regional fill-finish capacity.
• Digital dosing and automated delivery integration.

A formulation licensor can pursue milestone payments, regional rights, supply agreements, or co-development. The strongest negotiating position comes from clinical evidence that links the excipient system to lower postprandial glucose excursions, fewer infusion-set failures, reduced injection burden, or improved adherence.

Key Takeaways

• Humalog and Admelog use established insulin excipient systems based on m-cresol, glycerol, phosphate, zinc, and water.
• Lyumjev differentiates itself through an excipient strategy intended to accelerate insulin lispro absorption.
• Conventional lispro has limited basic patent protection and is exposed to price competition.
• The strongest commercial opportunities are ultra-rapid onset, U-200 and higher concentrations, pump stability, preservative reduction, and connected delivery.
• Excipients affect aggregation, zinc association, tonicity, preservation, absorption, pump compatibility, and shelf life.
• A conventional follow-on lispro is primarily a scale and access business.
• A differentiated excipient formulation can support stronger pricing and patent protection, but it requires more demanding clinical, device, and regulatory evidence.
• The key market barriers are manufacturing consistency, payer access, cold-chain reliability, device compatibility, and formulation-specific intellectual property.

FAQs About Insulin Lispro Excipient Strategy

Can m-cresol be removed from insulin lispro?

Yes, but removal requires a redesigned container and dosing system, such as a single-use cartridge or disposable presentation. Multidose products need effective antimicrobial control.

Does insulin lispro require zinc?

Most commercial lispro formulations use zinc to support insulin stability and association. A developer may alter zinc concentration or replace the system, but it must demonstrate equivalent stability, potency, and clinical performance.

Are Humalog and Admelog excipients identical?

They use broadly similar excipient systems, but product specifications, manufacturing processes, concentrations, container systems, and approved labeling must be compared directly.

Is Lyumjev a generic version of Humalog?

No. Lyumjev is an insulin lispro-aabc product developed with an ultra-rapid absorption profile. It is differentiated by formulation and clinical pharmacology rather than positioned as a conventional Humalog copy.

Which excipient has the greatest commercial value in rapid-acting insulin?

No single excipient determines value. The strongest commercial position comes from a validated combination that improves absorption or device performance while maintaining stability, tolerability, manufacturability, and regulatory support.

References

1. Eli Lilly and Company. (2024). Humalog insulin lispro injection prescribing information. U.S. Food and Drug Administration.

2. Sanofi-Aventis U.S. LLC. (2024). Admelog insulin lispro injection prescribing information. U.S. Food and Drug Administration.

3. Eli Lilly and Company. (2024). Lyumjev insulin lispro-aabc injection prescribing information. U.S. Food and Drug Administration.

4. U.S. Food and Drug Administration. (2020). Transition of certain biological products formerly approved under the Federal Food, Drug, and Cosmetic Act to the Public Health Service Act. FDA.

5. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. FDA.